新型冠状病毒感染(COVID-19)后的继发性硬化性胆管炎:一项多中心回顾性研究
这项德国9家三级医疗中心、127例继发性硬化性胆管炎(SSC)患者的回顾性多中心研究比较了COVID-SSC与危重症患者SSC(SSC-CIP)。COVID-SSC在COVID-19诊断后中位91天发生,患者均接受广泛重症监护治疗(中位机械通气48天)。UDCA使用和高血清白蛋白水平与无移植生存率升高独立相关,肝硬化与更差结局相关;作者认为UDCA可能是有前景的治疗选择,但需未来前瞻性试验证实。
要点
- COVID-SSC在COVID-19诊断后中位91天发生,患者均接受广泛重症监护治疗(中位机械通气48天)。
- COVID-SSC与SSC-CIP临床参数大多相当,无移植生存率与其他形式SSC无差异(P = .443,log-rank检验)。
- UDCA使用(OR 0.36,95%CI .16-.80,P = .013;log-rank P < .001)和高血清白蛋白水平(OR 0.40,95%CI .17-.96,P = .040)与无移植生存率升高独立相关。
核心结论
- COVID-SSC与CIP-SSC具有相同的临床表型、病程和发病危险因素。
- UDCA可能是SSC有前景的治疗选择,但需未来前瞻性试验证实作者的研究发现。
研究设计与样本
- 回顾性、多中心研究,纳入德国9家三级医疗中心的127例SSC患者。
- 比较COVID-SSC与SSC-CIP,并进行logistic回归分析探讨影响无移植生存率的因素。
主要发现
- 24例为COVID-SSC,77例为SSC-CIP,26例为其他形式SSC。
- COVID-SSC在COVID-19诊断后中位91天发生,所有患者均接受广泛重症监护治疗(中位机械通气48天)。
- COVID-SSC与SSC-CIP在大多数临床参数上相当,无移植生存率与其他形式SSC无差异(P = .443,log-rank检验)。
- 在整个队列中,UDCA使用(OR 0.36,95%CI .16-.80,P = .013;log-rank P < .001)和高血清白蛋白水平(OR 0.40,95%CI .17-.96,P = .040)与无移植生存率升高独立相关。
- 肝硬化(OR 2.52,95%CI 1.01-6.25,P = .047)与更差结局相关;多重耐药微生物(MDRO)定植或感染未影响患者生存。
关键数值与推荐
- UDCA使用与无移植生存率升高独立相关(OR 0.36,95%CI .16-.80,P = .013;log-rank P < .001)。
- 高血清白蛋白水平与无移植生存率升高独立相关(OR 0.40,95%CI .17-.96,P = .040)。
- 肝硬化与更差结局相关(OR 2.52,95%CI 1.01-6.25,P = .047)。
- COVID-SSC与SSC-CIP的无移植生存率与其他形式SSC无差异(P = .443,log-rank检验)。
- MDRO定植或感染未影响患者生存。
临床怎么用
- 作者认为UDCA可能是SSC有前景的治疗选择,但需未来前瞻性试验证实。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary sclerosing cholangitis (SSC) is a rare disease with poor prognosis. Cases of SSC have been reported following coronavirus disease 2019 (COVID-SSC). The aim of this study was to compare COVID-SSC to SSC in critically ill patients (SSC-CIP) and to assess factors influencing transplant-free survival. METHODS: In this retrospective, multicenter study involving 127 patients with SSC from 9 tertiary care centers in Germany, COVID-SSC was compared to SSC-CIP and logistic regression analyses were performed investigating factors impacting transplant-free survival. RESULTS: Twenty-four patients had COVID-SSC, 77 patients SSC-CIP, and 26 patients other forms of SSC. COVID-SSC developed after a median of 91 days following COVID-19 diagnosis. All patients had received extensive intensive care treatment (median days of mechanical ventilation, 48). Patients with COVID-SSC and SSC-CIP were comparable in most of the clinical parameters and transplant-free survival was not different from other forms of SSC (P = .443, log-rank test). In the overall cohort, the use of ursodeoxycholic acid (UDCA) (odds ratio [OR], 0.36 [95% confidence interval {CI}, .16-.80], P = .013; log-rank P < .001) and high serum albumin levels (OR, 0.40 [95% CI, .17-.96], P = .040) were independently associated with an increased transplant-free survival, while the presence of liver cirrhosis (OR, 2.52 [95% CI, 1.01-6.25], P = .047) was associated with worse outcome. Multidrug-resistant organism (MDRO) colonization or infection did not impact patients' survival. CONCLUSIONS: COVID-SSC and CIP-SSC share the same clinical phenotype, course of the disease, and risk factors for its development. UDCA may be a promising therapeutic option in SSC, though future prospective trials are needed to confirm our findings.
引用
- Hunyady P, Streller L, Rüther DF, et al. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study. Clin Infect Dis. 2023. PMID: 35809032. doi:10.1093/cid/ciac565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。